Analyst Highlights Growth Catalysts for Merck (MRK) Stock

We recently published Wall Street Analysts Like These 10 Stocks. Merck & Co., Inc. (NYSE:MRK) is one of the stocks analysts were recently talking about.

Bill Nygren, Oakmark Funds partner and CIO, recently said during a program on CNBC that he likes Merck & Co., Inc. (NYSE:MRK). Here is how the analyst made the bull case for the stock:

“Merck has some other really interesting assets including strong franchises in vaccines, which is another controversy area today. But we think that will continue to be a good profit source for them. They have a good business in animal health, and then in the pipeline they have a lot of experiments of combining KEYTRUDA with other drugs to more target specific cancers, and we think there’s a reasonable chance that at least one of those will be successful.”

Photo by Mohamed Hadji on Unsplash

Impax US Sustainable Economy Fund stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its second quarter 2025 investor letter:

“Merck & Co., Inc. (NYSE:MRK) (Health Care, Pharmaceuticals) has a high Corporate Resilience score, and is contributing to a more robust and sustainable health care system through its leading drug and vaccine discovery. The stock’s weakness in Q2 was driven by a combination of concerns about its drug pipeline, particularly the competition from generic versions of Keytruda, and weaker market sentiment around Health Care stocks.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.